Gain (loss) on available-for-sale debt securities
Royalty Pharma Gain (loss) on available-for-sale debt securities decreased by 127.7% to -$6.68M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 103.6%, from -$3.28M to -$6.68M. Over 4 years (FY 2021 to FY 2025), Gain (loss) on available-for-sale debt securities shows an upward trend with a 26.6% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
Reflects market interest rate fluctuations and credit quality changes in the company's investment portfolio.
Detailed definition
The change in fair value of debt securities held as available-for-sale that has not yet been realized through a sale. Th...
Peer comparison
Standard for any company with significant treasury or financial services investment holdings.
other_debt_securities_available_for_sale_unrealized_gain_lossHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $14.02M | -$14.89M | $9.61M | -$16.58M | $70.32M | $44.24M | -$104.80M | $32.30M | $82.90M | $7.30M | $108.34M | $46.42M | -$200.00K | $57.68M | $51.01M | -$3.28M | -$27.42M | $52.48M | $24.08M | -$6.68M |
| QoQ Change | — | -206.2% | +164.6% | -272.5% | +524.2% | -37.1% | -336.9% | +130.8% | +156.7% | -91.2% | >999% | -57.2% | -100.4% | >999% | -11.6% | -106.4% | -735.7% | +291.4% | -54.1% | -127.7% |
| YoY Change | — | — | — | — | +401.8% | +397.2% | <-999% | +294.8% | +17.9% | -83.5% | +203.4% | +43.7% | -100.2% | +690.1% | -52.9% | -107.1% | <-999% | -9.0% | -52.8% | -103.6% |
Gain (loss) on available-for-sale debt securities at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's gain (loss) on available-for-sale debt securities?
- Royalty Pharma (RPRX) reported gain (loss) on available-for-sale debt securities of -$6.68M in Q1 2026.
- How has Royalty Pharma's gain (loss) on available-for-sale debt securities changed year-over-year?
- Royalty Pharma's gain (loss) on available-for-sale debt securities decreased by 103.6% year-over-year, from -$3.28M to -$6.68M.
- What is the long-term trend for Royalty Pharma's gain (loss) on available-for-sale debt securities?
- Over 4 years (2021 to 2025), Royalty Pharma's gain (loss) on available-for-sale debt securities has grown at a 26.6% compound annual growth rate (CAGR), from $17.86M to $45.86M.
- What does gain (loss) on available-for-sale debt securities mean?
- The change in value of debt investments that have not yet been sold.